Cancer

February 3, 2019

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) [MAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 3/February/2019, 10.39 pm

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors […]
January 31, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing   MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells […]
January 30, 2019

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm

What we say: Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports here that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic […]
January 27, 2019

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SAV1/WW45, PP2A, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 27/January/2019, `11.47 pm

What we say: Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports here that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic […]